Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Carcinoma 3Fallopian Tube Neoplasms 2Sarcoma 1Renal Insufficiency 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1Congenital Abnormalities 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 47Nivolumab 34Sunitinib 18Cyclophosphamide 18Everolimus 17Ipilimumab 15cabozantinib 14pazopanib 13Bevacizumab 13fludarabine 12atezolizumab 11temsirolimus 10Magnetic Resonance Spectroscopy 10Sorafenib 9aldesleukin 8Specimen Handling 8Paclitaxel 8Sirolimus 7CTLA-4 Antigen 7Axitinib 7belzutifan 6Radiosurgery 6Oxaliplatin 6Interleukin-2 6Fluorouracil 6spartalizumab 5avelumab 5Leucovorin 5Irinotecan 5Docetaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Renal Cell × trebananib × Clear all
NCT01548482 2015-10-06

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡